Home Cart Sign in  
Chemical Structure| 38819-10-2 Chemical Structure| 38819-10-2

Structure of 9-β-D-Arabinofuranosylguanine
CAS No.: 38819-10-2

Chemical Structure| 38819-10-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

9-beta-Arabinosylguanine is an inducer of apoptosis, inhibitor of DNA synthesis, an antimetabolite, and antineoplastic.

Synonyms: AraG; ara-Guanosine; Ara-G , ara-Guanosine, Guanine Arabinoside

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of 9-β-D-Arabinofuranosylguanine

CAS No. :38819-10-2
Formula : C10H13N5O5
M.W : 283.24
SMILES Code : O=C1NC(N)=NC2=C1N=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3O
Synonyms :
AraG; ara-Guanosine; Ara-G , ara-Guanosine, Guanine Arabinoside
MDL No. :MFCD00065486
InChI Key :NYHBQMYGNKIUIF-FJFJXFQQSA-N
Pubchem ID :135499520

Safety of 9-β-D-Arabinofuranosylguanine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00866671 - Completed - Denmark ... More >> GSK Investigational Site Aahur N, Denmark GSK Investigational Site Aalborg, Denmark, DK-9100 GSK Investigational Site Koebenhavn Oe, Denmark, 2100 GSK Investigational Site Odense C, Denmark France GSK Investigational Site Bordeaux cedex, France, 33076 GSK Investigational Site Lille Cedex, France, 59037 GSK Investigational Site Nantes Cedex 1, France, 44093 GSK Investigational Site Paris Cedex 10, France, 75475 GSK Investigational Site Paris cedex 12, France, 75571 GSK Investigational Site Paris Cedex 19, France, 75935 GSK Investigational Site Vandoeuvre-Les-Nancy, France, 54511 Germany GSK Investigational Site Essen, Nordrhein-Westfalen, Germany, 45122 GSK Investigational Site Hamburg, Germany, 20246 Israel GSK Investigational Site Beer-Sheva, Israel, 84101 GSK Investigational Site Haifa, Israel, 31096 GSK Investigational Site Petach-Tikva, Israel GSK Investigational Site Ramat Gan, Israel, 52621 Italy GSK Investigational Site Bologna, Emilia-Romagna, Italy, 40137 Netherlands GSK Investigational Site Rotterdam, Netherlands, 3015 GJ Poland GSK Investigational Site Bydgoszcz, Poland GSK Investigational Site Lublin, Poland, 20-093 GSK Investigational Site Warszawa, Poland, 00-576 GSK Investigational Site Warszawa, Poland, 02-781 GSK Investigational Site Wroclaw, Poland, 50-345 Russian Federation GSK Investigational Site Krasnodar, Russian Federation, 350007 GSK Investigational Site Moscow, Russian Federation, 117997 GSK Investigational Site Moscow, Russian Federation, 119049 Spain GSK Investigational Site Barcelona, Spain, 08035 GSK Investigational Site Boadilla del Monte (Madrid), Spain, 28660 GSK Investigational Site Madrid, Spain, 28009 GSK Investigational Site Madrid, Spain, 28047 Less <<
NCT03311672 Non-small Cell Lung Cancer Phase 2 Recruiting November 1, 2018 United States, California ... More >> University of California, San Francisco Recruiting San Francisco, California, United States, 94107 Contact: Dora Tao    415-514-6759    dora.tao@ucsf.edu Less <<
NCT03007719 Bladder Cancer Phase 2 Recruiting December 2018 United States, California ... More >> University of California, San Francisco Recruiting San Francisco, California, United States, 94158 Contact: Julie McCluggage, RN    877-827-3222    HDFCCC.CIP@ucsf.edu    Contact: Lissa Gray, NP    877-827-3222    HDFCCC.CIP@ucsf.edu Less <<
NCT03367962 Graft Versus Host Disease Phase 1 Recruiting December 2020 United States, California ... More >> Stanford Hospital Recruiting Stanford, California, United States, 94305 Contact: Krithika Rupnarayan, MPH,MBBS    650-736-0959    krupnara@stanford.edu Less <<
NCT00406757 Leukaemia, Lymphoblastic, Acut... More >>e and Lymphoma, Lymphoblastic Less << Phase 1 Completed - Japan ... More >> GSK Investigational Site Aichi, Japan, 460-0001 GSK Investigational Site Tokyo, Japan, 104-0045 GSK Investigational Site Tokyo, Japan, 104-8560 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.53mL

0.71mL

0.35mL

17.65mL

3.53mL

1.77mL

35.31mL

7.06mL

3.53mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories